Top > News Releases
Y’s Therapeutics Co., Ltd have been reduced the paid-in capital and capital reserve.
Tokyo, Japan, and San Bruno, CA -May 16th, 2009-
It has been approved at the 6th shareholders meeting held on March 31, 2009 and completed all the necessary legal processes on May 16, 2009 that the paid-in capital and capital reserve for Y’s Therapeutics Co., Ltd have been reduced both to Yen 100 million, respectively.
About Y's Therapeutics
Y's Therapeutics (http://www.ysthera.com) is a privately held biopharmaceutical company engaged
in the R&D of novel therapeutics for the treatment of inflammation-mediated diseases, cancer, and other unmet medical needs.
Y's focuses on the development of preclinical and early-stage clinical projects pursued through research collaborations and
in-licensing opportunities from academic institutions and biotech companies. Y's is seeking collaborative relationships,
including out-licensing of product rights and creation of joint ventures, for late-stage development,
manufacturing and commercialization of its portfolio products. The company currently has several projects
in its clinical and preclinical pipeline. Y's has operations in two locations, Y's Therapeutics Co., Ltd.,
of Tokyo, Japan, and Y's Therapeutics, Inc., of San Bruno, CA.
◈CONTACT◈
HR & Administrations Department
Y's Therapeutics Co., Ltd.
E-Mail：admin@ysthera.com
 |
 |
Top | Site Map | Access Map | Privacy Policy | Terms of Use |
